$AEON

Central Retail Corporation (CRC) said, in a Stock Exchange of Thailand filing, that its unit Central Food Retail (CFR) will buy AEON (Thailand) Co Ltd, which operates 30 MaxValu supermarkets and has 890 million baht registered capital. CRC plans to fund the deal with internal cash flow, rebrand stores as Tops, and add 900,000+ customers, plus land and a ready-to-eat processing center.

AEON Credit Service (M) Bhd said in its first-quarter 2027 results that younger and lower-income borrowers face higher financial stress, especially in personal and used-car financing. The company deployed AI voice bots to automate repayment follow-ups for lower-risk customers. Net profit was RM95.16m (+22.7% YoY), with non-performing loans at 2.6% and receivables write-offs at 1.4%.

Analysts issued multiple rating changes. Humana (HUM) was upgraded by Leerink to Outperform with a $513 target and by Piper Sandler to Overweight with a $463 target. Bloom Energy (BE), Sprouts (SFM), uniQure (QURE), and Core Scientific (CORZ) also saw upgrades. Las Vegas Sands (LVS) was downgraded to Hold by Argus. Other actions included P&G (PG), SiteOne (SITE), Capricor (CAPR), and Fannie Mae (FNMA).

Reuters reports a 7.1-magnitude earthquake in southern Japan killed at least 13 people and left thousands without power. Rescuers pulled eight survivors from a partially collapsed Aeon mall near Kumamoto, with three deaths and four workers unaccounted for; authorities are investigating a possible gas explosion. Nippon Paper Industries reported missing workers at a factory, and companies including Renesas, Sony, Tokyo Electron, Honda, and Toyota suspended operations.

Nichirei Corp said a system failure tied to unauthorized access began disrupting its frozen food shipments and refrigerated warehouse operations. The company, serving about 5,000 business clients, plans a gradual restart from Friday but gave no full recovery timeline and flagged possible personal data exposure. KFC Japan, Kura Sushi, Aeon subsidiaries, Don Quijote operator Pan Pacific, Ezaki Glico, and Imuraya reported ingredient shortages.

AEON Biopharma, Inc. (AEON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.4 6 aeon-20260713xex4d4.htm EX-4.4 M2561538.DOC;3 Exhibit 4.4 EXECUTION VERSION WARRANT AGENCY AGREEMENT THIS WARRANT AGENCY AGREEMENT (this “Agreement”), dated as of July 15, 2026, is entered into by and between AEON Biopharma, Inc., a Delaware corporation (the “Company”),

AEON Biopharma (AEON) priced an upsized underwritten public offering. It will raise about $13.75M in immediate gross proceeds, with total gross proceeds up to $43.3M if milestone warrants tied to ABP-450 are exercised for cash. The offering includes 42.69M shares at $0.3221 each. Proceeds fund ABP-450 development and working capital. Closing expected around July 15, 2026.

AEON Biopharma, Inc. (AEON) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. AEON Biopharma, Inc._June 17, 2026 0001837607 false 0001837607 2026-06-17 2026-06-17 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of ea

AEON Biopharma said it will present analytical and functional data supporting biosimilarity of its ABP-450 to BOTOX® at the American Headache Society’s 68th Annual Scientific Meeting in Orlando (June 4-7). The poster (abstract 2349958) by CMO Chad K. Oh cites 93%-99% LC-MS peptide sequence coverage with no variant peptides and LD50 potency results within predefined equivalence criteria.

AEON Biopharma, Inc. announced its financial results for the full year 2025, reporting a net loss of $39,222 thousand compared to a net income of $42,005 thousand in 2024. Despite the loss and a highly leveraged capital structure, the company advanced its ABP-450 biosimilar program with positive analytical data and favorable FDA feedback, and strengthened its balance sheet through a $6 million PIPE financing and debt reduction. The company expects to complete most analytical comparability work in 2026.